Ponnusamy, SuriyanHe, YaliHwang, Dong-JinThiyagarajan, ThirumagalHoutman, ReneBocharova, VeraSumpter, Bobby G.Fernandez, EliasJohnson, DanielDu, ZiyunPfeffer, Lawrence M.Getzenberg, Robert H.McEwan, Iain J.Miller, Duane D.Narayanan, Ramesh2020-09-022020-09-022019-11Ponnusamy, S, He, Y, Hwang, D-J, Thiyagarajan, T, Houtman, R, Bocharova, V, Sumpter, B G, Fernandez, E, Johnson, D, Du, Z, Pfeffer, L M, Getzenberg, R H, McEwan, I J, Miller, D D & Narayanan, R 2019, 'Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer', Clinical Cancer Research, vol. 25, no. 22, pp. 6764-6780. https://doi.org/10.1158/1078-0432.CCR-19-14581078-0432Mendeley: ff2ee6b2-d612-3083-bd9b-c5945063a762https://hdl.handle.net/2164/15067Acknowledgement. BGS acknowledges work performed at the Center for Nanophase Materials Sciences, a DOE Office of Science User Facility. VB acknowledges Laboratory Directed Research and Development program of Oak Ridge National Laboratory, managed by UTBattelle, LLC, for the U.S. Department of Energy.173710811engSDG 3 - Good Health and Well-beingprostate cancerCastration-Resistant Prostate Cancer (CRPC)androgen receptor (AR)AR degrader (SARD)coactivatorenzalutamide-resistant prostate cancerPHOSPHORYLATIONCYP17A1 INHIBITORSPLICE VARIANTANTITUMOR-ACTIVITYDIFFERENTIAL REGULATIONBREAST-CANCERANTIANDROGENGENEINCREASED SURVIVALABIRATERONERC0254 Neoplasms. Tumors. Oncology (including Cancer)OncologyCancer ResearchSupplementary DataRC0254Journal article10.1158/1078-0432.CCR-19-1458http://www.mendeley.com/research/orallybioavailable-androgen-receptor-degrader-potential-nextgeneration-therapeutic-enzalutamideresishttp://www.scopus.com/inward/record.url?scp=85074356016&partnerID=8YFLogxK2522